News

The physical activity component of the PAH-SYMPACT — a patient-reported measure of quality of life tailored for people with pulmonary arterial hypertension (PAH) — is an independent predictor of the risk of death among PAH patients, according to a new study from Australia. One unit increase in this parameter…

Direct oral anticoagulants (DOACs) — a type of blood thinner medication — are as safe and effective as vitamin K antagonists (VKAs), the standard blood thinner used to treat chronic thromboembolic pulmonary hypertension (CTEPH), according to a meta-analysis of published studies. The findings support the use of DOACs as a…

A SIRT3 protein deficiency in skeletal muscles, which are attached to bones, was related to pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a study shows. A lack of SIRT3 triggered the release of LOXL2, a protein that promotes lung tissue scarring, which stimulated the CNPY2…

The amount of normal-looking lung tissue visible on CT scans of the chest can help to predict survival outcomes and response to treatment in people with pulmonary hypertension (PH), a study found. The study, “Significance of normal lung volume on quantitative computed tomography analysis in Group…

Gemcitabine, a chemotherapy given to treat solid cancers, may drive the onset of pulmonary arterial hypertension (PAH) in patients or worsen existing PAH, a recent study reports. Stopping treatment with gemcitabine, with or without a subsequent PAH-approved treatment, led to clinical improvement or disease stabilization for a majority…

Treatment with Revatio (sildenafil) at a higher dose than the recommended and previously approved doses did not significantly increase mortality of adults with pulmonary arterial hypertension (PAH). That’s according to results from the Phase 3b/4 AFFILIATE trial (NCT02060487), which compared three treatment doses, each given three times…

Experts recommend taking Uptravi (selexipag) with food and slowly titrating it up, at a frequency of less than weekly or by raising one of the two daily doses, as tolerated, while caring for any side effects adults with pulmonary arterial hypertension (PAH) may be having. The recommendation came…

Chronic alcohol consumption damages the heart and blood vessels in ways that seem to set the stage for pulmonary arterial hypertension (PAH), according to a study in male rats. These findings “yield new insight into the adverse effect of ethanol on cardiopulmonary [heart and lung] health, providing a foundation…

Life support measures, specifically the need for assisted breathing, and elevated blood levels of bilirubin, a marker of liver damage, are among the factors that predict worse outcomes after a lung transplant in people with idiopathic pulmonary arterial hypertension (IPAH), a study reports. A new predictive model that includes…

Levels of fractional exhaled nitric oxide (FeNO) — a measure of how much nitric oxide a person exhales — may be used as a diagnostic tool for severe disease in people with idiopathic pulmonary arterial hypertension (iPAH), a study has found. Specifically, patients with FeNO levels lower than 23…

Pulmonary arterial hypertension (PAH) patients enrolled in a Phase 2b clinical trial testing AV-101, an inhaled formulation of imatinib, entered the trial with significant disease despite use of triple background therapy, according to data shared by developer Aerovate Therapeutics. The company said the study population will allow for…

AER-901, a new inhaled formulation of imatinib delivered via a specialized device, was predicted to reach 2-3 times higher levels in the lung tissue over standard inhalers among people with forms of pulmonary hypertension (PH), according to new data from Aerami Therapeutics, its developer. Having been proven to…